Aldoxorubicin: Interim Phase Ib/II data

Interim data from 36 evaluable patients with advanced sarcomas in an open-label, U.S. Phase Ib/II trial showed that 170 and 250 mg/m2 doses of aldoxorubicin plus ifosfamide and mesna led to an ORR of ...